ArticleCell death discovery2026
NRIP1 co-activates nuclear translocated FOXO3 to upregulate TFAM expression and promote radioresistance in non-small cell lung cancer.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Radioresistance remains a major obstacle in the treatment of non-small cell lung cancer (NSCLC). This study investigated the coordinated regulation of TFAM, FOXO3, and NRIP1 in NSCLC radioresistance. Radioresistant cell lines (A549-RR and H157-RR) were established to examine the effects of silencing these factors on cellular responses to radiation. In vivo, the impact of FOXO3 knockdown on tumor growth under irradiation was evaluated using A549-RR xenografts. Results show that TFAM expression was elevated in radioresistant cells, and its knockdown significantly restored radiosensitivity. ChIP-qPCR demonstrated direct FOXO3 binding to TFAM regulatory regions, establishing FOXO3 as an upstream transcriptional activator of TFAM. Silencing FOXO3 reduced TFAM expression and enhanced radiosensitivity, whereas LOM612, a FOXO nuclear relocator, promoted FOXO3 nuclear accumulation, upregulated TFAM, and reduced radiosensitivity. NRIP1 deficiency constrains FOXO3-dependent regulation of TFAM. Restoring NRIP1 selectively enhanced TFAM without affecting FOXO3 abundance, indicating its role as a coactivator. Co-immunoprecipitation confirmed FOXO3/NRIP1 interaction in NSCLC cells, with stronger interactions observed in radioresistant cells. Accordingly, NRIP1 silencing decreased TFAM levels and increased radiosensitivity. In vivo, FOXO3 knockdown markedly suppressed A549-RR tumor growth and improved radiotherapy response. Collectively, these findings indicate that nuclear accumulation of FOXO3 drives NSCLC radioresistance by transcriptionally upregulating TFAM, with NRIP1 enhancing this regulatory activity. Targeting FOXO3 may represent a promising strategy to enhance radiosensitivity in NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.